NANEMIAR research team had the honor of participating in the 3rd Congenital Anemia Patient Conference

We had the honor of participating in the 3rd Congenital Anemia Patient Conference held at the Barceló Occidental Hotel in Murcia (Spain) last June 17th, 2025. This event brought together healthcare professionals, patients, and families to share scientific advancements, personal experiences, and future perspectives regarding these rare diseases.

The conference was organized by the Region of Murcia through its Department of Health, in collaboration with the IMIB (Murcia Institute of Biosanitary Research), the Foundation for Health Training and Research of the Region of Murcia (FFIS), and the Murcia Health Service (SMS).

The opening ceremony featured remarks by Mª Fuensanta Martínez Lozano, Director of the FFIS, and Dr. Vanesa Roldán Schilling, Head of the Hematology Department at the Virgen de la Arrixaca University Hospital.

One of the most moving moments was the testimony of Mr. Secundino Sacristán, a beta-thalassemia patient and president of ALHETA (Spanish Association for the Fight against Hemoglobinopathies and Thalassemias), who emphasized the importance of patient associations in coping with the disease. Another highlight was the heartfelt speech from Isabel Melero, a relative of a patient, who shared a valuable perspective from the family’s point of view.

We also had the opportunity to hear from María Dolores Muñoz Navarro, a patient with pyruvate kinase deficiency, who shared her inspiring journey “from patient to researcher” as a current higher education student in laboratory studies

The scientific segment of the conference featured a round table on hematopoietic transplantation, gene therapy, and other advancements, with presentations by Dr. Miguel Blanquer, Dr. Eduardo Salido, and Dr. Ana Belén Pérez, researchers from the hematopoietic transplant group at IMIB.

In this segment, the speakers also discussed the current progress of the European @nanemiar Project, as well as their views on the potential inclusion of mRNA nanoparticles as a therapeutic tool for patients with congenital anemias.

This gathering was made possible thanks to the sponsorship of INVERSUS and the support of collaborating entities such as Salud 21, the Spanish Group for Erythropathology, ALHETA, and ASAFE.

Cathegory: NANEMIAR event / patient event

Read the full press article (in Spanish) - III Conference with patients with congenital anemia (Source of information: Salud 21 Murcia)

"NANEMIAR project is funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them."